As the ASX200 hovers near the 8,000-point mark, investors are keeping a watchful eye on market shifts influenced by recent tariff announcements and sector performance. In such a climate, penny stocks—often representing smaller or newer companies—can still provide intriguing opportunities for growth. Despite their somewhat outdated label, these stocks may offer value when supported by strong financial health and fundamentals.
Top 10 Penny Stocks In Australia
| Name | Share Price | Market Cap | Rewards & Risks |
| CTI Logistics (ASX:CLX) | A$1.685 | A$135.72M | ✅ 4 ⚠️ 2 View Analysis > |
| EZZ Life Science Holdings (ASX:EZZ) | A$1.53 | A$72.17M | ✅ 4 ⚠️ 2 View Analysis > |
| IVE Group (ASX:IGL) | A$2.47 | A$380.83M | ✅ 4 ⚠️ 2 View Analysis > |
| GTN (ASX:GTN) | A$0.60 | A$115.38M | ✅ 3 ⚠️ 2 View Analysis > |
| Bisalloy Steel Group (ASX:BIS) | A$3.38 | A$160.38M | ✅ 3 ⚠️ 1 View Analysis > |
| Regal Partners (ASX:RPL) | A$1.88 | A$631.99M | ✅ 4 ⚠️ 3 View Analysis > |
| Navigator Global Investments (ASX:NGI) | A$1.70 | A$833.14M | ✅ 5 ⚠️ 3 View Analysis > |
| SHAPE Australia (ASX:SHA) | A$3.00 | A$248.22M | ✅ 3 ⚠️ 1 View Analysis > |
| NRW Holdings (ASX:NWH) | A$2.60 | A$1.19B | ✅ 5 ⚠️ 1 View Analysis > |
| LaserBond (ASX:LBL) | A$0.37 | A$43.53M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 988 stocks from our ASX Penny Stocks screener.
Let's dive into some prime choices out of the screener.
Berkeley Energia (ASX:BKY)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Berkeley Energia Limited is involved in the exploration and development of mineral properties in Spain, with a market cap of A$258.56 million.
Operations: Currently, the company does not report any revenue segments.
Market Cap: A$258.56M
Berkeley Energia Limited, with a market cap of A$258.56 million, is a pre-revenue company focused on mineral exploration in Spain. Despite its pre-revenue status, the company has recently achieved profitability, reporting net income of A$0.83 million for the half year ending December 2024. The management team and board are seasoned with average tenures of 9.5 and 13 years respectively, which may provide stability as they navigate growth challenges typical for penny stocks. Berkeley is debt-free and its short-term assets significantly exceed liabilities, indicating strong financial health despite low revenue generation at this stage.
- Unlock comprehensive insights into our analysis of Berkeley Energia stock in this financial health report.
- Gain insights into Berkeley Energia's historical outcomes by reviewing our past performance report.
Helloworld Travel (ASX:HLO)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Helloworld Travel Limited is a travel distribution company operating in Australia, New Zealand, and internationally with a market cap of A$237.71 million.
Operations: The company's revenue is primarily derived from Travel Operations in Australia (A$153.71 million), New Zealand (A$36.06 million), and the Rest of World (A$3.72 million), along with contributions from Transport, Logistics, and Warehousing (A$15.20 million).
Market Cap: A$237.71M
Helloworld Travel Limited, with a market cap of A$237.71 million, operates in the travel distribution sector with significant revenue streams from Australia and New Zealand. Despite recent earnings decline, the company remains debt-free and maintains strong asset coverage over liabilities. The dividend yield of 7.53% is not well-supported by free cash flow, raising sustainability concerns despite a recent increase to A$0.08 per share. Trading at a price-to-earnings ratio of 9.1x, below the Australian market average, it presents as relatively undervalued with analysts forecasting potential stock price growth of 67%. Management's experience averages 2.9 years, providing moderate stability amidst industry challenges.
- Click to explore a detailed breakdown of our findings in Helloworld Travel's financial health report.
- Evaluate Helloworld Travel's prospects by accessing our earnings growth report.
Imugene (ASX:IMU)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Imugene Limited is an Australian clinical stage immuno-oncology company focused on developing immunotherapies to activate the immune system against cancer, with a market cap of A$194.14 million.
Operations: Imugene's revenue segment is primarily focused on the research, development, and commercialisation of health technologies with a reported figure of -A$1.84 million.
Market Cap: A$194.14M
Imugene Limited, with a market cap of A$194.14 million, is pre-revenue and unprofitable, reporting a net loss of A$48.34 million for the half-year ending December 2024. Despite this, its short-term assets significantly exceed liabilities, and it holds more cash than total debt. The company recently appointed Darren Keamy as CFO and Company Secretary, bringing extensive biopharmaceutical financial expertise to potentially enhance strategic direction. Imugene was added to the S&P/ASX Emerging Companies Index but dropped from other indices in March 2025. Shareholder dilution has been minimal over the past year amidst ongoing capital raises for operational funding.
- Jump into the full analysis health report here for a deeper understanding of Imugene.
- Gain insights into Imugene's future direction by reviewing our growth report.
Make It Happen
- Investigate our full lineup of 988 ASX Penny Stocks right here.
- Ready For A Different Approach? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Imugene might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com